DNMT3A and acute myeloid leukemia: MDS cases harboring DNMT3A R882 mutations showed significantly higher risk of AML transformation (25.8%, vs. 1.7%, p=.0001) than the non-882 group (Figure 4A), which is not entirely due to increased frequency of excess blasts, as MDS-EB cases harboring DNMT3A R882 mutations also showed significantly higher risk of AML transformation than the non-R882 group (34.5%, vs. 0%, p=.01).